Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsFRA:MYD +1.90%42 EV-to-OCF is 63.23 as of Sep. 15, 2026, which is 440% above its 10-year median of 11.70. GuruFocus rates FRA:MYD with a GF Score™ of 42/100 and a GF Value™ of €9.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 92.96% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Myriad Genetics's Enterprise Value is €394.9 Mil.
Myriad Genetics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €6.2 Mil. Therefore, Myriad Genetics's EV-to-OCF for today is 63.23.
The historical rank and industry rank for Myriad Genetics's EV-to-OCF or its related term are showing as below:
FRA:MYD'
s EV-to-OCF Range Over the Past 10 Years
Min: -446.64 Med: 11.7 Max: 375.24
Current: 54.8
During the past 13 years, the highest EV-to-OCF of Myriad Genetics was 375.24. The lowest was -446.64. And the median was 11.70.
FRA:MYD's EV-to-OCF is ranked worse than 92.96% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.92
vs FRA:MYD: 54.80
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Myriad Genetics's PE Ratio (TTM) for today is calculated as:
Myriad Genetics's share price for today is €2.899.
Myriad Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.025.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Myriad Genetics EV-to-OCF Related Terms
Myriad Genetics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Myriad Genetics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's EV-to-OCF falls into.
Myriad Genetics's current Enterprise Value is €394.9 Mil.
Myriad Genetics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (FRA:MYD) has a EV-to-OCF of 63.23 as of Sep. 15, 2026. This is 440% above median its historical median of 11.70. According to the industry distribution chart, Myriad Genetics ranks #198 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 93%.
Is Myriad Genetics' EV-to-OCF too high?
Myriad Genetics' current EV-to-OCF of 63.23 is 440% above median its 10-year median of 11.70. The Medical Diagnostics & Research industry median EV-to-OCF is 5.92. Myriad Genetics' value of 63.23 is 968.1% above this industry median. Based on the distribution chart, Myriad Genetics ranks #198 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' EV-to-OCF compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #198 out of 213 companies for EV-to-OCF. This places Myriad Genetics in the lower half of its industry. The industry median EV-to-OCF is 5.92. Myriad Genetics' value of 63.23 is 968.1% above this benchmark. While the company's 10-year median is 11.70 vs. the industry median of 5.92, Myriad Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 5.92, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current EV-to-OCF of 63.23 is 968.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 5.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current EV-to-OCF is 63.23, which is 440% above median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €2.90 — trading 69.5% below its estimated fair value. The current EV-to-OCF is 63.23, which is 440% above median its 10-year median of 11.70 and 968.1% above the Medical Diagnostics & Research industry median of 5.92. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current EV-to-OCF is 63.23 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (FRA:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.90 is trading 69.5% below its estimated GF Value™ of €9.49.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for FRA:MYD:
EV-to-OCF: 63.23 (440% above median its 10-year median of 11.70)
GF Value™: €9.49 vs. price of €2.90 (69.5% below fair value)
Industry Position: 968.1% above the Medical Diagnostics & Research median (#198 of 213)
No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
42GF Score
Get the complete analysis for FRA:MYD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MYD has been successfully added to your 
